Phase 4 N=226 Obesity, Oral Contraception, and Ovarian Suppression
Ovarian Suppression
Primary: Risk of Oral Contraceptive (OC) Failure Due to Less Contraceptive-mediated Ovarian Suppression. — 54; 28; 11; 12 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=302 Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men
Neoplasms, Prostate
Primary: Number of Participants With Prostate Cancer (PCa) Progression [Restricted Crude Rate Analysis: Number of Participants With PCa Divided by Number of Participants in the…
Phase 4 N=246 Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis
Psoriasis
Primary: Participants With a Status of Mild or Better on Physician Global Assessment at Month 12 — 166 Participants
Phase 4 N=29 Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness
Type 1 Diabetes
Primary: Change in A1C From Baseline to Week 15 — -1.7; -1.0 percent glycated hemoglobin
Phase 4 N=30 Escitalopram in Patients With Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Effect of Escitalopram After 8 Weeks of Treatment in Patients With GAD Using the Hamilton Anxiety Scale (HAMA) — 13.1 scores on a scale
Phase 4 N=30 Escitalopram in Patients With Social Anxiety Disorder
Social Anxiety Disorder
Primary: Effect of Escitalopram After 12 Weeks Using the Clinical Global Impression (CGI-I) — 2.1 scores on a scale
Phase 4 N=30 A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
Multiple Sclerosis, Relapsing-Remitting
Primary: Time From Baseline to First Multiple Sclerosis Relapse (in Weeks) — 35.5; 40.9 weeks — p=0.1384
Phase 4 N=130 Antidepressant Medication Plus Donepezil for Treating Late-life Depression
Depression · Dementia
Primary: Global Cognitive Performance — -0.47; -0.47; -0.23; -0.65 Z-score
Phase 4 N=3,235 Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
Acute Coronary Syndrome
Primary: Number of Participants With Composite of Major Bleeding, Minor Bleeding, or Major Vascular Access Site Complications During the Peri-PCI Period — 48; 58 participants…
Phase 4 N=179 A Multiple Myeloma Trial in Patients With Bone Metastases
Multiple Myeloma
Primary: The Number of Participants With a Significant Increase in Serum Creatinine at 12 Months — 17; 13 Participants
Phase 4 N=115 Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy
Postoperative Nausea and Vomiting
Primary: Cumulative Incidence of Emesis — 8; 20 participants
Phase 4 N=277 A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease
Alzheimer's Disease
Primary: Total Brain Atrophy Rate Estimated Using Brain Boundary Shift Integral (BBSI) — 15.24; 15.32 mL/year — p=0.9754
Phase 4 N=138 Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis
Plaque Psoriasis
Primary: Number of Participants Who Were a Success (Clear/Almost Clear) of Plaque Psoriasis at Week 4 Based on the Overall Disease Severity (ODS), Full Ordinal Scale From…
Phase 4 N=69 Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant
Complications; Contraceptive · Female Lactation
Primary: Time to Lactogenesis Stage II — 64.3; 65.2 hours — p=<0.05
Phase 4 N=40 The Utility of Nexium in Chronic Cough and Reflux Disease
Cough · GERD
Primary: Change in Cough-Specific Quality of Life Questionnaire — 9.8; 5.8 participants